Guide · 14 min · 2026-08-25
Pharma Deviation & CAPA Management: 5-Why, Ishikawa Fishbone & Risk Matrix Guide
Definitive GxP quality guide to pharmaceutical deviation categorization, root cause analysis (5-Why, Fishbone), CAPA effectiveness verification, and 21 CFR Part 11 audit trails.
1. Regulatory Expectations for Deviation Investigations
Global health authorities (US FDA, MHRA, CDSCO) mandate that pharmaceutical manufacturers thoroughly investigate every unexplained discrepancy, out-of-specification (OOS) result, or process deviation. Weak root-cause investigations and generic 'retrain operator' CAPAs represent the #1 cited deficiency in FDA 483 warning letters.
2. The 2-Phase Investigation Methodology in Novaqis QMS
Novaqis QMS enforces structured 2-phase investigations: • Phase 1 (Laboratory & Process Checklists): Systematic elimination of analytical, sampling, and instrument errors within 24 hours. • Phase 2 (Cross-Functional Root Cause Analysis): Interactive visual 5-Why trees and Ishikawa Fishbone diagrams linked directly to raw material lots in Novaqis ERP and batch steps in Novaqis BRM. • Automated CAPA Effectiveness Tracking: System-enforced 30/60/90-day review cycles with recurrence prevention metrics.
Experience the Enterprise GxP Suite Live
Discover how Novaqis unifies Document Management (DMS), Quality Management (eQMS), Training (LMS), Laboratory Informatics (LIMS), Batch Records (BRM), and ERP on a single high-availability architecture.